Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents with Psychiatric Disorders

Robert L Findling, Robert Goldman, Yu Yuan Chiu, Robert Silva, Fengbin Jin, Andrei Pikalov, Antony Loebel

Research output: Contribution to journalArticle

Abstract

Purpose The aim of this study was to evaluate the pharmacokinetic (PK) profile and tolerability of lurasidone in children and adolescents with a range of psychiatric disorders. Methods This multicenter, open-label, single and multiple ascending-dose study of the PK profile of lurasidone (20, 40, 80, 120, and 160 mg/d) enrolled outpatients aged 6 to 17 years with a diagnosis of attention deficit/hyperactivity disorder, bipolar spectrum disorder, or other psychiatric disorder. Serial blood samples were collected for analysis of PK parameters, including Cmax, Tmax, and AUC0-24. Findings Exposure (Cmax and AUC0-24) to lurasidone and its active metabolites showed linear increases across the entire dose range. Slope estimates (95% CI) across the dose range studied was 0.90 ng · h/mL (0.74-1.06) for AUC0-24 and 0.70 ng/mL (0.52-0.87) for Cmax on day 10 or 12. Lurasidone exposure, after multiple-dose administration in this child and adolescent population, was similar to exposure observed at steady state in adults. The effects of dose on exposure to the 3 active metabolites of lurasidone were linear and similar after the administration of single and multiple doses. Adverse events were qualitatively similar to those reported in adults. Discontinuations due to adverse events were dose related, with doses

Original languageEnglish (US)
Pages (from-to)2788-2797
Number of pages10
JournalClinical Therapeutics
Volume37
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Adolescent Psychiatry
Pharmacokinetics
Psychiatry
Attention Deficit Disorder with Hyperactivity
Bipolar Disorder
Outpatients
Lurasidone Hydrochloride
Population

Keywords

  • bipolar I disorder
  • lurasidone
  • pediatric
  • pharmacokinetic
  • schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents with Psychiatric Disorders. / Findling, Robert L; Goldman, Robert; Chiu, Yu Yuan; Silva, Robert; Jin, Fengbin; Pikalov, Andrei; Loebel, Antony.

In: Clinical Therapeutics, Vol. 37, No. 12, 01.12.2015, p. 2788-2797.

Research output: Contribution to journalArticle

Findling, Robert L ; Goldman, Robert ; Chiu, Yu Yuan ; Silva, Robert ; Jin, Fengbin ; Pikalov, Andrei ; Loebel, Antony. / Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents with Psychiatric Disorders. In: Clinical Therapeutics. 2015 ; Vol. 37, No. 12. pp. 2788-2797.
@article{42db5caf69aa483eb0a77b8eb2b96a17,
title = "Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents with Psychiatric Disorders",
abstract = "Purpose The aim of this study was to evaluate the pharmacokinetic (PK) profile and tolerability of lurasidone in children and adolescents with a range of psychiatric disorders. Methods This multicenter, open-label, single and multiple ascending-dose study of the PK profile of lurasidone (20, 40, 80, 120, and 160 mg/d) enrolled outpatients aged 6 to 17 years with a diagnosis of attention deficit/hyperactivity disorder, bipolar spectrum disorder, or other psychiatric disorder. Serial blood samples were collected for analysis of PK parameters, including Cmax, Tmax, and AUC0-24. Findings Exposure (Cmax and AUC0-24) to lurasidone and its active metabolites showed linear increases across the entire dose range. Slope estimates (95{\%} CI) across the dose range studied was 0.90 ng · h/mL (0.74-1.06) for AUC0-24 and 0.70 ng/mL (0.52-0.87) for Cmax on day 10 or 12. Lurasidone exposure, after multiple-dose administration in this child and adolescent population, was similar to exposure observed at steady state in adults. The effects of dose on exposure to the 3 active metabolites of lurasidone were linear and similar after the administration of single and multiple doses. Adverse events were qualitatively similar to those reported in adults. Discontinuations due to adverse events were dose related, with doses",
keywords = "bipolar I disorder, lurasidone, pediatric, pharmacokinetic, schizophrenia",
author = "Findling, {Robert L} and Robert Goldman and Chiu, {Yu Yuan} and Robert Silva and Fengbin Jin and Andrei Pikalov and Antony Loebel",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.clinthera.2015.11.001",
language = "English (US)",
volume = "37",
pages = "2788--2797",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "12",

}

TY - JOUR

T1 - Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents with Psychiatric Disorders

AU - Findling, Robert L

AU - Goldman, Robert

AU - Chiu, Yu Yuan

AU - Silva, Robert

AU - Jin, Fengbin

AU - Pikalov, Andrei

AU - Loebel, Antony

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Purpose The aim of this study was to evaluate the pharmacokinetic (PK) profile and tolerability of lurasidone in children and adolescents with a range of psychiatric disorders. Methods This multicenter, open-label, single and multiple ascending-dose study of the PK profile of lurasidone (20, 40, 80, 120, and 160 mg/d) enrolled outpatients aged 6 to 17 years with a diagnosis of attention deficit/hyperactivity disorder, bipolar spectrum disorder, or other psychiatric disorder. Serial blood samples were collected for analysis of PK parameters, including Cmax, Tmax, and AUC0-24. Findings Exposure (Cmax and AUC0-24) to lurasidone and its active metabolites showed linear increases across the entire dose range. Slope estimates (95% CI) across the dose range studied was 0.90 ng · h/mL (0.74-1.06) for AUC0-24 and 0.70 ng/mL (0.52-0.87) for Cmax on day 10 or 12. Lurasidone exposure, after multiple-dose administration in this child and adolescent population, was similar to exposure observed at steady state in adults. The effects of dose on exposure to the 3 active metabolites of lurasidone were linear and similar after the administration of single and multiple doses. Adverse events were qualitatively similar to those reported in adults. Discontinuations due to adverse events were dose related, with doses

AB - Purpose The aim of this study was to evaluate the pharmacokinetic (PK) profile and tolerability of lurasidone in children and adolescents with a range of psychiatric disorders. Methods This multicenter, open-label, single and multiple ascending-dose study of the PK profile of lurasidone (20, 40, 80, 120, and 160 mg/d) enrolled outpatients aged 6 to 17 years with a diagnosis of attention deficit/hyperactivity disorder, bipolar spectrum disorder, or other psychiatric disorder. Serial blood samples were collected for analysis of PK parameters, including Cmax, Tmax, and AUC0-24. Findings Exposure (Cmax and AUC0-24) to lurasidone and its active metabolites showed linear increases across the entire dose range. Slope estimates (95% CI) across the dose range studied was 0.90 ng · h/mL (0.74-1.06) for AUC0-24 and 0.70 ng/mL (0.52-0.87) for Cmax on day 10 or 12. Lurasidone exposure, after multiple-dose administration in this child and adolescent population, was similar to exposure observed at steady state in adults. The effects of dose on exposure to the 3 active metabolites of lurasidone were linear and similar after the administration of single and multiple doses. Adverse events were qualitatively similar to those reported in adults. Discontinuations due to adverse events were dose related, with doses

KW - bipolar I disorder

KW - lurasidone

KW - pediatric

KW - pharmacokinetic

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84951905176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951905176&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2015.11.001

DO - 10.1016/j.clinthera.2015.11.001

M3 - Article

VL - 37

SP - 2788

EP - 2797

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 12

ER -